Preclinical Evaluation of 111In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-positive Cancer Models

Journal of Nuclear Medicine - China
doi 10.2967/jnumed.118.220095
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Society of Nuclear Medicine

Related search

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates

Pharmaceutical Research
Organic ChemistryBiotechnologyMolecular MedicinePharmacologyPharmaceutical Science
2014English

Optimization of a PEGylated Glucuronide-Monomethylauristatin E Linker for Antibody–Drug Conjugates

Molecular Cancer Therapeutics
Cancer ResearchOncology
2016English

Antibody-Drug Conjugates in Bladder Cancer

Bladder Cancer
OncologyUrology
2018English

Drug-Adapted Cancer Cell Lines as Preclinical Models of Acquired Resistance

2019English

Preclinical Evaluation of a GFRA1 Targeted Antibody-Drug Conjugate in Breast Cancer

Oncotarget
Oncology
2018English

The Application of in Vitro Models in a Preclinical Safety Evaluation of New Drug Candidates

Farmacja Polska
2018English

Bispecifics and Antibody–drug Conjugates: A Positive Synergy

Drug Discovery Today: Technologies
BiotechnologyDrug DiscoveryMolecular Medicine
2018English

Curaxin CBL0137 Eradicates Drug Resistant Cancer Stem Cells and Potentiates Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer

Oncotarget
Oncology
2014English

Preclinical Investigation of PEGylated Tumor Necrosis Factor in Dogs With Spontaneous Tumors: Phase I Evaluation

Clinical Cancer Research
Cancer ResearchOncology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy